Today's Rundown Featured Story | | | Monday, May 18, 2020 Moderna’s COVID-19 prompted an immune response similar to those seen in patients who have recovered from infection. Eight patients who received the two lowest dose levels—25 micrograms and 100 micrograms—developed neutralizing antibodies against the virus two weeks after receiving their second dose. |
|
|---|
|
Top Stories Monday, May 18, 2020 Healthcare is in a state of flux and once the immediate emergency of the current COVID-19 pandemic passes the industry will not return to business as usual, experts say. Here are four changes to expect in healthcare going forward. Monday, May 18, 2020 Verily has launched a new clinical research effort focused on COVID-19 antibody testing and exploring the body’s immune response to the novel coronavirus. Monday, May 18, 2020 Federal prosecutors turned up the heat in recent months on a generic price-fixing probe that had targeted some of the industry's biggest players before COVID-19 slowed the hunt. Teva, the biggest target in that investigation, has reportedly bailed on settlement talks in a decision meant to test the government's resolve. Friday, May 15, 2020 There are serious questions surrounding antibody testing and what we can actually glean from them. It felt like a waste of money. But I got the test anyway. Now what? Monday, May 18, 2020 Moderna shares leapt about 30% after unveiling early data showing its vaccine candidate led eight trial participants to elicit neutralizing antibodies. Elsewhere, Verily launched a new clinical research effort focused on COVID-19, with an initial focus on coronavirus antibody testing. Monday, May 18, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Monday, May 18, 2020 CureVac announced that its lead COVID-19 mRNA vaccine candidate generated “high levels” of virus-neutralizing titers in animal models and that it will launch a phase 1/2a clinical trial next month. But with Moderna's equally optimistic statements about a mouse trial of its mRNA vaccine candidate, some analysts are raising questions about what the preclinical data really means. Monday, May 18, 2020 Fitbit aims to wield its fitness-focused supply chain to start building its own COVID-19 ventilator and plans to submit its designs to the FDA in the near future, CEO James Park told CNBC. Monday, May 18, 2020 Microsoft and UnitedHealth Group are launching a free smartphone app that businesses and employees can use to digitally screen for COVID-19 symptoms and clear those who can return to work. Monday, May 18, 2020 As the pandemic plays out, political divisions have unfolded around hydroxychloroquine and reopening economies, for starters. Monday, May 18, 2020 Washington-based Premera Blue Cross is launching a new virtual primary care plan for employers. Here's why they say COVID-19 is making a clear use case. Monday, May 18, 2020 The FDA authorized a new at-home collection kit that allows people to take their own nasal swab samples and then mail them overnight to a laboratory to be tested with different authorized coronavirus diagnostics. Monday, May 18, 2020 AstraZeneca wants to answer questions COPD and asthma patients might have when it comes to COVID-19. A new, unbranded TV ad invites people with respiratory conditions to a YouTube channel AZ created with a series of explainer videos specific to the novel coronavirus. |
|
